Treatment inhibits key process that enables cancer cells to multiply.
Researchers in London plan to begin clinical trials on a significant new treatment for multiple myeloma by the end of next year.
In laboratory testing, the drug, known as DTP3, killed myeloma cells within human cells and mice without causing any toxic side effects. In a paper published on October 13, 2014 in Cancer Cells, researchers outlined how the drug inhibits a key process that allows cancer cells to multiply.
“Lab studies suggest that DTP3 could have therapeutic benefit for patients with multiple myeloma and potentially several other types of cancer, but we will need to confirm this in our clinical trials, the first of which will start next year,” said lead researcher Professor Guido Franzoso in a press release.
DTP3 was developed through an evaluation of the mechanisms that enable cancer cells to continue multiplying beyond their normal lifespan. Specifically, the researchers studied a protein called nuclear factor kappa B (NF-kB), which plays a key role in inflammation, in addition to immune and stress response systems.